World leading expert in copper-67 joins Clarity’s SAB
Sydney, Australia 1 March 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the appointment of the world leading expert in copper-67 isotope (Cu-67 or 67Cu) production, Jon Stoner, to Clarity’s Scientific Advisory…